Celebrex Patent Settlement Could Give Teva De Facto Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s blockbuster pain drug would go generic in December under a royalty-bearing deal; litigation against other ANDA holders continues.